Welcome to our dedicated page for Achilles Therapeutics Plc news (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics Plc stock.
Achilles Therapeutics plc (ACHL) is a clinical-stage biopharmaceutical company that has focused on AI-powered precision T cell therapies targeting clonal neoantigens in solid tumors. News about Achilles provides insight into how the company has developed and adjusted its programs, platforms, collaborations, and corporate structure over time.
Company announcements have covered clinical updates from its CHIRON and THETIS Phase I/IIa trials in advanced non-small cell lung cancer and recurrent or metastatic melanoma, including data on clonal neoantigen-reactive T cells (cNeT), enhanced host conditioning, and the performance of its VELOS manufacturing process. Releases have also described translational science findings related to tumor evolution, immune evasion, and neoantigen selection using the PELEUS bioinformatics platform.
Investors and researchers following ACHL can find news on strategic collaborations, such as the research collaboration with Arcturus Therapeutics to explore second-generation personalized mRNA cancer vaccines based on clonal neoantigens. Additional updates have detailed the sale of technology assets and data from the TRACERx NSCLC study and the Material Acquisition Platform (MAP) to AstraZeneca, marking significant changes in the company’s asset base and focus.
Recent corporate news has included strategic reviews, the discontinuation of the TIL-based cNeT program, closure of the CHIRON and THETIS trials, workforce and governance changes, and steps related to Nasdaq listing status. These include Nasdaq deficiency notices, a transfer to the Nasdaq Capital Market, and later, the company’s stated intention to voluntarily delist its ADSs and pursue a members’ voluntary liquidation. This news page aggregates such releases so readers can follow the evolution of Achilles Therapeutics’ clinical efforts, partnerships, financial updates, and planned wind-down.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Achilles Therapeutics (NASDAQ: ACHL) announced on April 21, 2023, that it received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement for its American Depositary Shares (ADS). The company has until October 18, 2023, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Despite this notice, Achilles' ADSs will continue to trade on the Nasdaq Global Select Market. The company is actively monitoring its bid price and may consider options to regain compliance. Achilles is developing AI-powered precision T cell therapies for cancer treatments and has ongoing Phase I/IIa trials for patients with advanced non-small cell lung cancer and metastatic melanoma.
Achilles Therapeutics has announced the granting of US patent 11,634,773, which focuses on immunotherapy targeting neoantigens linked to specific HLA alleles preserved in tumors. This patent enables treatment via various modalities such as vaccines and T cell therapies. The proprietary sequence-based method allows identification of HLA loss, crucial for developing effective cancer treatments. This technology is integrated into the company's PELEUS™ bioinformatics platform, facilitating personalized treatment strategies in clinical trials. Achilles, a clinical-stage biopharmaceutical company, is actively working on T cell therapies targeting clonal neoantigens in ongoing trials for advanced non-small cell lung cancer and metastatic melanoma.
FAQ
What is the current stock price of Achilles Therapeutics Plc (ACHL)?
What is the market cap of Achilles Therapeutics Plc (ACHL)?
